Kadcyla

Dosage: 160 mg

Specification: 1 vial per box

Manufacturer: Roche 

Origin: Switzerland

 

Online Inquiry

kadcyla01-sized

Kadcyla Indications

Kadcyla is a combination of targeted HER2 antibody and microtubule inhibitor for patients with her2-positive, metastatic breast cancer who have previously received trastuzumab and a type of ibutane, either separately or in combination, as a single drug. Patients should have one of the following conditions:
(1) receive treatment for the metastatic disease before,
(2) recurrence of the disease during the completion of adjuvant treatment or within 6 months.

contact us

contact-email
Sunray Pharma logo

Sunray Pharma

We provide customers with quality products and services.

看不清,请点击我!

If you would like to leave us a comment please go to contact us

contact-clo
top